• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Beyond Air Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    6/22/26 4:15:30 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care
    Get the next $XAIR alert in real time by email
    false 0001641631 0001641631 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): June 18, 2026

     

    Beyond Air, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-38892   47-3812456

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    900 Stewart Avenue, Suite 301

    Garden City, NY 11530

    (Address of Principal Executive Offices and Zip Code)

     

    (516) 665-8200

    Registrant’s Telephone Number, Including Area Code

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $.0001 per share   XAIR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On June 18, 2026, Beyond Air, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). On April 20, 2026, the record date for stockholders entitled to notice of, and to vote at, the Special Meeting, 12,692,684 shares of the Company’s common stock (“Common Stock”) were outstanding. The holders of 6,487,760 shares of Common Stock were present at the Special Meeting, either in person or represented by proxy, constituting a quorum.

     

    The following matters were considered at the Special Meeting:

     

    Proposal 1. Reverse Stock Split Proposal

     

    The Company’s stockholders granted the board of directors of the Company (the “Board”) authority, in its sole discretion, prior to the one-year anniversary of the Special Meeting, to effect a reverse stock split of the outstanding shares of the Company’s Common Stock (the “Reverse Stock Split”), at a reverse split ratio of between 1-for-2 and 1-for-20 as determined by the Board, whereby every 2 to 20 shares of the issued and outstanding Common Stock shall be combined into one share of issued and outstanding Common Stock. The Reverse Stock Split will not change the number of authorized shares of our capital stock. The voting results were as follows:

     

    For     Against     Abstain     Broker Non-Vote  
    5,177,506     1,222,793       87,461     0  

     

    The Reverse Stock Split proposal was approved by the Company’s stockholders. The results reported above are final voting results. No other matters were considered or voted upon at the meeting, except a proposal to adjourn the Special Meeting of Stockholders to a later date, if necessary, to permit further solicitation and vote proxies in the event there were not sufficient votes in favor of the Reverse Stock Split Proposal. Based upon the voting results, the latter was not applicable.

     

    Item 8.01. Other Events.

     

    On June 18, 2026, immediately following the receipt of stockholder approval at the Special Meeting, the Board approved a reverse stock split ratio of 1-for-20, whereby every 20 shares of the issued and outstanding Common Stock shall be combined into one share of issued and outstanding Common Stock (the “Approved Ratio”). The Company expects to effect the Reverse Stock Split at the Approved Ratio at such time as determined by the Company’s Board, subject to the filing and effectiveness of a certificate of amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware.

     

    The Company intends to implement the Reverse Stock Split to raise the per share bid price of the Common Stock above $1.00 per share for at least ten trading days and bring the Company back into compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed, the Company must demonstrate compliance with the Bid Price Rule on or before July 31, 2026. The Company cannot provide assurance that the Reverse Stock Split will be implemented at the Approved Ratio, implemented in a timely manner or at all, or that if implemented, that it will achieve the desired effects.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BEYOND AIR, Inc.
       
    Date: June 22, 2026 By: /s/ Daniel Moorhead
      Name: Daniel Moorhead
      Title Chief Financial Officer

     

     

    Get the next $XAIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XAIR

    DatePrice TargetRatingAnalyst
    7/17/2025$11.00Buy
    D. Boral Capital
    6/25/2024Buy → Neutral
    BTIG Research
    7/28/2023$10.00Overweight
    Piper Sandler
    6/15/2023$15.00Buy
    BTIG Research
    11/12/2021$12.00 → $16.00Buy
    Truist Securities
    More analyst ratings

    $XAIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Moorhead Daniel J

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:17:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Moorhead Daniel J

    3 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:15:38 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Lee Yoori

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    11/24/25 5:22:10 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day. Conference Call & WebcastFriday, June 26th @ 8:00 a.m. ETDomestic:1-877-407-0784International:1-201-689-8560Conference ID:13761239 Webcast: A webcast of the live confe

    6/22/26 4:01:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air, Inc. Urges Stockholders to Vote "FOR" All Proposals Ahead of the Upcoming Special Meeting

    Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies GARDEN CITY, N.Y., June 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company") today reminded stockholders of record to submit their votes ahead of the Company's upcoming Special Meeting of Stockholders (the "Special Meeting"), scheduled for Thursday, June 18, 2026 at 4:30 p.m. Eastern Time. The Special Meeting will be held in person at the Company's offices located at 900 Stewart Avenue, Suite 30

    6/10/26 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

    GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC's ("Nasdaq" or the "Exchange") Listing Rule 5550(a)(2) (the "Bid Price Rule") by July 31, 2026. The Company is fully compliant with all other continued listing requirements. "We appreciate the Panel's thoughtful review and support of our compliance plan,"

    6/1/26 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Lisi Steven A. bought $19,491 worth of shares (6,000 units at $3.25), increasing direct ownership by 0.18% to 3,327,411 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    7/23/25 4:05:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    3/17/25 8:15:33 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    2/21/25 5:00:14 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    SEC Filings

    View All

    Beyond Air Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    6/22/26 4:15:30 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air Inc. filed SEC Form 8-K: Other Events

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    6/1/26 4:30:41 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.

    SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    5/15/26 4:51:59 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Beyond Air with a new price target

    D. Boral Capital initiated coverage of Beyond Air with a rating of Buy and set a new price target of $11.00

    7/17/25 8:02:31 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air downgraded by BTIG Research

    BTIG Research downgraded Beyond Air from Buy to Neutral

    6/25/24 8:04:46 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Beyond Air with a new price target

    Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00

    7/28/23 7:37:57 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Leadership Updates

    Live Leadership Updates

    View All

    Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

    GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company's current Chief Commercial Officer and Director, as Chief Executive Officer, effective today. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of th

    3/26/26 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

    Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California. HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. "We are excited to appoint Dr. Monson as

    6/1/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

    HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief Financial Officer. Ms. Jones joins Beyond Cancer™ with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid. Follow

    5/17/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Financials

    Live finance-specific insights

    View All

    Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day. Conference Call & WebcastFriday, June 26th @ 8:00 a.m. ETDomestic:1-877-407-0784International:1-201-689-8560Conference ID:13761239 Webcast: A webcast of the live confe

    6/22/26 4:01:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & WebcastMonday, November 11th @ 4:30 PM ETDomestic: 1-877-407-0784International: 1-201-689-8560Conference ID: 13749670Webcast: A webcast of the live conference call can be accessed by visiting the Eve

    10/29/24 4:22:08 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

    LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of

    6/28/22 4:10:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Beyond Air Inc.

    SC 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    10/9/24 1:35:29 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    10/3/24 3:09:56 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    3/7/24 12:29:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care